Roche (RHHBY) is deploying more than 3,500 NVIDIA (NVDA) Blackwell GPUs across hybrid cloud and on-premises environments in the U.S. and Europe, expanding on an existing collaboration to turn AI and accelerated computing into a core operating capability across its pharmaceutical and diagnostics businesses, the company said Monday. “We’re excited to innovate at the intersection of science and technology to accelerate drug and diagnostic solutions development,” said Wafaa Mamilli, chief digital and technology officer at Roche. “With high-quality data and smarter AI, we will be able to leverage those insights both in pharma as well as in our diagnostic divisions.”
Claim 30% Off TipRanks
Trade NVDA with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVDA:
- Nvidia remains a Top Pick following GTC, says Cantor Fitzgerald
- Nvidia: Long-Term Datacenter Visibility and AI Inference Momentum Underpin Buy Rating
- Nvidia: Expanding AI Platform, $1 Trillion Blackwell/Vera Rubin Demand, and Durable Competitive Moat Justify Buy Rating
- Nvidia: Durable AI-Led Growth and Earnings Upside Support Top Pick ‘Buy’ Rating and $300 Target
- Nvidia: Reinforcing AI Inference Leadership and Platform Dominance Drive Multi‑Year Upside Potential